dementia

Dementia, encompassing Alzheimer disease, vascular, Lewy body, and frontotemporal subtypes, affects approximately 55 million people globally with no curative treatment. Anti-amyloid immunotherapy has recently achieved regulatory approval for Alzheimer disease, representing the first disease-modifying advance. Prevention strategies targeting vascular risk factors, hearing loss, and social isolation are gaining clinical traction alongside drug development.